

Wendy Barclay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4286022/publications.pdf>

Version: 2024-02-01

166
papers

15,799
citations

28242

55
h-index

26591

107
g-index

247
all docs

247
docs citations

247
times ranked

21256
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. <i>Nature</i> , 2021, 599, 114-119.	13.7	1,041
2	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <i>Cell</i> , 2022, 185, 467-484.e15.	13.5	788
3	Cellular immune correlates of protection against symptomatic pandemic influenza. <i>Nature Medicine</i> , 2013, 19, 1305-1312.	15.2	757
4	Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 183-195.	4.6	585
5	The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. <i>Nature Microbiology</i> , 2021, 6, 899-909.	5.9	556
6	RIG-I Detects Viral Genomic RNA during Negative-Strand RNA Virus Infection. <i>Cell</i> , 2010, 140, 397-408.	13.5	508
7	Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. <i>Lancet Microbe</i> , The, 2020, 1, e245-e253.	3.4	441
8	Host and viral determinants of influenza A virus species specificity. <i>Nature Reviews Microbiology</i> , 2019, 17, 67-81.	13.6	390
9	Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. <i>Nature Communications</i> , 2020, 11, 3523.	5.8	357
10	The origins of SARS-CoV-2: A critical review. <i>Cell</i> , 2021, 184, 4848-4856.	13.5	330
11	A Complicated Message: Identification of a Novel PB1-Related Protein Translated from Influenza A Virus Segment 2 mRNA. <i>Journal of Virology</i> , 2009, 83, 8021-8031.	1.5	318
12	The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. <i>Journal of General Virology</i> , 2020, 101, 791-797.	1.3	300
13	Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. <i>Nature</i> , 2021, 594, 88-93.	13.7	293
14	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. <i>Nature Medicine</i> , 2022, 28, 1031-1041.	15.2	281
15	Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. <i>Lancet</i> , The, 2021, 397, 1178-1181.	6.3	279
16	The mechanism of resistance to favipiravir in influenza. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 11613-11618.	3.3	243
17	Species difference in ANP32A underlies influenza A virus polymerase host restriction. <i>Nature</i> , 2016, 529, 101-104.	13.7	228
18	Investigating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Surface and Air Contamination in an Acute Healthcare Setting During the Peak of the Coronavirus Disease 2019 (COVID-19) Pandemic in London. <i>Clinical Infectious Diseases</i> , 2021, 73, e1870-e1877.	2.9	227

#	ARTICLE	IF	CITATIONS
19	Infection of Human Airway Epithelium by Human and Avian Strains of Influenza A Virus. <i>Journal of Virology</i> , 2006, 80, 8060-8068.	1.5	224
20	SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. <i>Nature Communications</i> , 2021, 12, 905.	5.8	168
21	Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 40-49.	7.0	145
22	The M1 matrix protein controls the filamentous phenotype of influenza A virus. <i>Virology</i> , 2004, 321, 144-153.	1.1	143
23	Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. <i>PLoS Pathogens</i> , 2021, 17, e1010022.	2.1	139
24	SARS-CoV-2 one year on: evidence for ongoing viral adaptation. <i>Journal of General Virology</i> , 2021, 102, .	1.3	137
25	A phase I clinical trial of a PER.C6 ⁺ cell grown influenza H7 virus vaccine. <i>Vaccine</i> , 2009, 27, 1889-1897.	1.7	136
26	Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. <i>Thorax</i> , 2020, 75, 1082-1088.	2.7	133
27	Viral determinants of influenza A virus host range. <i>Journal of General Virology</i> , 2014, 95, 1193-1210.	1.3	132
28	A prenylated dsRNA sensor protects against severe COVID-19. <i>Science</i> , 2021, 374, eabj3624.	6.0	124
29	Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. <i>Science</i> , 2021, 374, eabl9551.	6.0	111
30	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. <i>Lancet, The</i> , 2021, 398, 223-237.	6.3	110
31	Handheld Point-of-Care System for Rapid Detection of SARS-CoV-2 Extracted RNA in under 20 min. <i>ACS Central Science</i> , 2021, 7, 307-317.	5.3	106
32	Rapid increase in Omicron infections in England during December 2021: REACT-1 study. <i>Science</i> , 2022, 375, 1406-1411.	6.0	99
33	Population antibody responses following COVID-19 vaccination in 212,102 individuals. <i>Nature Communications</i> , 2022, 13, 907.	5.8	94
34	REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. <i>Wellcome Open Research</i> , 2020, 5, 200.	0.9	93
35	Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. <i>Lancet Microbe, The</i> , 2020, 1, e300-e307.	3.4	92
36	Resurgence of SARS-CoV-2: Detection by community viral surveillance. <i>Science</i> , 2021, 372, 990-995.	6.0	91

#	ARTICLE	IF	CITATIONS
37	Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. <i>Lancet Regional Health - Europe</i> , The, 2021, 4, 100098.	3.0	91
38	Host ANP32A mediates the assembly of the influenza virus replicase. <i>Nature</i> , 2020, 587, 638-643.	13.7	89
39	Evidence for Avian and Human Host Cell Factors That Affect the Activity of Influenza Virus Polymerase. <i>Journal of Virology</i> , 2010, 84, 9978-9986.	1.5	88
40	Knowns and unknowns of influenza B viruses. <i>Future Microbiology</i> , 2016, 11, 119-135.	1.0	88
41	Transfer of the Amino-Terminal Nuclear Envelope Targeting Domain of Human MX2 Converts MX1 into an HIV-1 Resistance Factor. <i>Journal of Virology</i> , 2014, 88, 9017-9026.	1.5	87
42	The time course of the humoral immune response to rhinovirus infection. <i>Epidemiology and Infection</i> , 1989, 103, 659-669.	1.0	85
43	Accumulation of Human-Adapting Mutations during Circulation of A(H1N1)pdm09 Influenza Virus in Humans in the United Kingdom. <i>Journal of Virology</i> , 2014, 88, 13269-13283.	1.5	84
44	Glycomic Characterization of Respiratory Tract Tissues of Ferrets. <i>Journal of Biological Chemistry</i> , 2014, 289, 28489-28504.	1.6	82
45	Viral factors in influenza pandemic risk assessment. <i>ELife</i> , 2016, 5, .	2.8	82
46	Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England. <i>Science</i> , 2022, 376, .	6.0	78
47	NS1 Proteins of Avian Influenza A Viruses Can Act as Antagonists of the Human Alpha/Beta Interferon Response. <i>Journal of Virology</i> , 2007, 81, 2318-2327.	1.5	72
48	The Short Stalk Length of Highly Pathogenic Avian Influenza H5N1 Virus Neuraminidase Limits Transmission of Pandemic H1N1 Virus in Ferrets. <i>Journal of Virology</i> , 2013, 87, 10539-10551.	1.5	72
49	Avian Influenza Virus Glycoproteins Restrict Virus Replication and Spread through Human Airway Epithelium at Temperatures of the Proximal Airways. <i>PLoS Pathogens</i> , 2009, 5, e1000424.	2.1	68
50	ANP32 Proteins Are Essential for Influenza Virus Replication in Human Cells. <i>Journal of Virology</i> , 2019, 93, .	1.5	68
51	Species specific differences in use of ANP32 proteins by influenza A virus. <i>ELife</i> , 2019, 8, .	2.8	68
52	A Reverse Genetics Approach for Recovery of Recombinant Influenza B Viruses Entirely from cDNA. <i>Journal of Virology</i> , 2002, 76, 11744-11747.	1.5	67
53	Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. <i>F1000Research</i> , 2015, 4, 30.	0.8	63
54	Restrictions to the Adaptation of Influenza A Virus H5 Hemagglutinin to the Human Host. <i>Journal of Virology</i> , 2004, 78, 502-507.	1.5	61

#	ARTICLE	IF	CITATIONS
55	Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 466-470.	1.3	61
56	Mutations in H5N1 Influenza Virus Hemagglutinin that Confer Binding to Human Tracheal Airway Epithelium. <i>PLoS ONE</i> , 2009, 4, e7836.	1.1	60
57	M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. <i>JCI Insight</i> , 2017, 2, e91868.	2.3	59
58	Pause on Avian Flu Transmission Research. <i>Science</i> , 2012, 335, 400-401.	6.0	58
59	Mutations in haemagglutinin that affect receptor binding and pH stability increase replication of a PR8 influenza virus with H5 HA in the upper respiratory tract of ferrets and may contribute to transmissibility. <i>Journal of General Virology</i> , 2013, 94, 1220-1229.	1.3	58
60	The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. <i>Nature Communications</i> , 2021, 12, 4068.	5.8	57
61	Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. <i>F1000Research</i> , 2015, 4, 30.	0.8	57
62	The Effect of the PB2 Mutation 627K on Highly Pathogenic H5N1 Avian Influenza Virus Is Dependent on the Virus Lineage. <i>Journal of Virology</i> , 2013, 87, 9983-9996.	1.5	56
63	Ferrets as Models for Influenza Virus Transmission Studies and Pandemic Risk Assessments. <i>Emerging Infectious Diseases</i> , 2018, 24, 965-971.	2.0	56
64	SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. <i>BMJ</i> , The, 2021, 372, n423.	3.0	56
65	Usability and Acceptability of Home-based Self-testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies for Population Surveillance. <i>Clinical Infectious Diseases</i> , 2021, 72, e384-e393.	2.9	55
66	REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. <i>Wellcome Open Research</i> , 2020, 5, 200.	0.9	55
67	Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance. <i>Scientific Reports</i> , 2016, 6, 29793.	1.6	53
68	Alterations in Receptor Binding Properties of Recent Human Influenza H3N2 Viruses Are Associated with Reduced Natural Killer Cell Lysis of Infected Cells. <i>Journal of Virology</i> , 2007, 81, 11170-11178.	1.5	52
69	Adjuvant-Free Immunization with Hemagglutinin-Fc Fusion Proteins as an Approach to Influenza Vaccines. <i>Journal of Virology</i> , 2011, 85, 3010-3014.	1.5	47
70	An early warning system for emerging SARS-CoV-2 variants. <i>Nature Medicine</i> , 2022, 28, 1110-1115.	15.2	47
71	Receptor Binding Profiles of Avian Influenza Virus Hemagglutinin Subtypes on Human Cells as a Predictor of Pandemic Potential. <i>Journal of Virology</i> , 2011, 85, 1875-1880.	1.5	46
72	Investigation of Influenza Virus Polymerase Activity in Pig Cells. <i>Journal of Virology</i> , 2013, 87, 384-394.	1.5	46

#	ARTICLE	IF	CITATIONS
73	Variability in H9N2 haemagglutinin receptor-binding preference and the pH of fusion. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-7.	3.0	46
74	Urgent challenges in implementing live attenuated influenza vaccine. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e25-e32.	4.6	46
75	Mouse Models of Influenza Infection with Circulating Strains to Test Seasonal Vaccine Efficacy. <i>Frontiers in Immunology</i> , 2018, 9, 126.	2.2	46
76	Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway. <i>Cell Reports</i> , 2022, 38, 110344.	2.9	46
77	Lack of transmission of a human influenza virus with avian receptor specificity between ferrets is not due to decreased virus shedding but rather a lower infectivity in vivo. <i>Journal of General Virology</i> , 2011, 92, 1822-1831.	1.3	45
78	Transmission of a 2009 H1N1 Pandemic Influenza Virus Occurs before Fever Is Detected, in the Ferret Model. <i>PLoS ONE</i> , 2012, 7, e43303.	1.1	44
79	Low Dose Influenza Virus Challenge in the Ferret Leads to Increased Virus Shedding and Greater Sensitivity to Oseltamivir. <i>PLoS ONE</i> , 2014, 9, e94090.	1.1	43
80	Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 759-765.	1.3	42
81	Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing. <i>Journal of Virology</i> , 2019, 93, .	1.5	42
82	Influenza A virus PB1-F2 protein prolongs viral shedding in chickens lengthening the transmission window. <i>Journal of General Virology</i> , 2016, 97, 2516-2527.	1.3	42
83	Unstable Polymerase-Nucleoprotein Interaction Is Not Responsible for Avian Influenza Virus Polymerase Restriction in Human Cells. <i>Journal of Virology</i> , 2013, 87, 1278-1284.	1.5	41
84	Immune Escape Variants of H9N2 Influenza Viruses Containing Deletions at the Hemagglutinin Receptor Binding Site Retain Fitness <i>in Vivo</i> and Display Enhanced Zoonotic Characteristics. <i>Journal of Virology</i> , 2017, 91, .	1.5	41
85	Host Determinants of Influenza RNA Synthesis. <i>Annual Review of Virology</i> , 2019, 6, 215-233.	3.0	39
86	SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 355-366.	5.2	39
87	Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. <i>Nature Microbiology</i> , 2022, 7, 1180-1188.	5.9	39
88	Antiviral Screening of Multiple Compounds against Ebola Virus. <i>Viruses</i> , 2016, 8, 277.	1.5	37
89	Computational and molecular analysis of conserved influenza A virus RNA secondary structures involved in infectious virion production. <i>RNA Biology</i> , 2016, 13, 883-894.	1.5	36
90	Entry of the bat influenza H17N10 virus into mammalian cells is enabled by the MHC class II HLA-DR receptor. <i>Nature Microbiology</i> , 2019, 4, 2035-2038.	5.9	35

#	ARTICLE	IF	CITATIONS
91	Transmission Studies Resume for Avian Flu. <i>Science</i> , 2013, 339, 520-521.	6.0	34
92	Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 665-676.	5.2	34
93	SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures. <i>Thorax</i> , 2022, 77, 259-267.	2.7	34
94	Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. <i>PLoS Pathogens</i> , 2018, 14, e1006821.	2.1	32
95	A common TMPRSS2 variant has a protective effect against severe COVID-19. <i>Current Research in Translational Medicine</i> , 2022, 70, 103333.	1.2	30
96	Elucidating the Interactions between Influenza Virus Polymerase and Host Factor ANP32A. <i>Journal of Virology</i> , 2020, 94, .	1.5	29
97	Generation of candidate human influenza vaccine strains in cell culture “rehearsing the European response to an H7N1 pandemic threat. <i>Influenza and Other Respiratory Viruses</i> , 2007, 1, 157-166.	1.5	28
98	One-way trip: Influenza virus' adaptation to gallinaceous poultry may limit its pandemic potential. <i>BioEssays</i> , 2015, 37, 204-212.	1.2	28
99	Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission. <i>PLoS Pathogens</i> , 2020, 16, e1008395.	2.1	28
100	A Single Amino Acid in the HA of pH1N1 2009 Influenza Virus Affects Cell Tropism in Human Airway Epithelium, but Not Transmission in Ferrets. <i>PLoS ONE</i> , 2011, 6, e25755.	1.1	28
101	Assays to Measure the Activity of Influenza Virus Polymerase. <i>Methods in Molecular Biology</i> , 2018, 1836, 343-374.	0.4	26
102	RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals. <i>PLoS Pathogens</i> , 2019, 15, e1007601.	2.1	26
103	Swine ANP32A Supports Avian Influenza Virus Polymerase. <i>Journal of Virology</i> , 2020, 94, .	1.5	26
104	Influenza Virus with Increased pH of Hemagglutinin Activation Has Improved Replication in Cell Culture but at the Cost of Infectivity in Human Airway Epithelium. <i>Journal of Virology</i> , 2019, 93, .	1.5	25
105	Characterising viable virus from air exhaled by H1N1 influenza-infected ferrets reveals the importance of haemagglutinin stability for airborne infectivity. <i>PLoS Pathogens</i> , 2020, 16, e1008362.	2.1	25
106	Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium. <i>Nature Communications</i> , 2022, 13, 1609.	5.8	24
107	Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model. <i>PLoS Pathogens</i> , 2021, 17, e1009527.	2.1	23
108	Favipiravir-resistant influenza A virus shows potential for transmission. <i>PLoS Pathogens</i> , 2021, 17, e1008937.	2.1	23

#	ARTICLE	IF	CITATIONS
109	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	2.7	23
110	Regulation of influenza A virus mRNA splicing by CLK1. <i>Antiviral Research</i> , 2019, 168, 187-196.	1.9	21
111	An influenza reassortant with polymerase of pH1N1 and NS gene of H3N2 influenza A virus is attenuated in vivo. <i>Journal of General Virology</i> , 2012, 93, 998-1006.	1.3	20
112	Development of a Reverse Genetics System Enabling the Rescue of Recombinant Avian Influenza Virus A/Turkey/England/50-92/91 (H5N1). <i>Avian Diseases</i> , 2007, 51, 393-395.	0.4	19
113	Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease. <i>Mucosal Immunology</i> , 2014, 7, 89-100.	2.7	19
114	SARS-CoV-2 variants of concern alpha, beta, gamma and delta have extended ACE2 receptor host ranges. <i>Journal of General Virology</i> , 2022, 103, .	1.3	19
115	Inactivation of SARS-CoV-2 in chlorinated swimming pool water. <i>Water Research</i> , 2021, 205, 117718.	5.3	17
116	Influenza Pandemics. <i>Advances in Experimental Medicine and Biology</i> , 2012, 719, 81-103.	0.8	16
117	Multisystem screening reveals SARS-CoV-2 in neurons of the myenteric plexus and in megakaryocytes. <i>Journal of Pathology</i> , 2022, 257, 198-217.	2.1	16
118	Pandemic risks from bird flu. <i>BMJ: British Medical Journal</i> , 2004, 328, 238-239.	2.4	15
119	Appropriately smoothing prevalence data to inform estimates of growth rate and reproduction number. <i>Epidemics</i> , 2022, 40, 100604.	1.5	15
120	Host Cell Factors That Interact with Influenza Virus Ribonucleoproteins. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038307.	2.9	14
121	Probing the receptor interactions of an H5 avian influenza virus using a baculovirus expression system and functionalised poly(acrylic acid) ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 4038-4047.	1.4	13
122	Ultrastructure of cell trafficking pathways and coronavirus: how to recognise the wolf amongst the sheep. <i>Journal of Pathology</i> , 2020, 252, 346-357.	2.1	13
123	NB protein does not affect influenza B virus replication in vitro and is not required for replication in or transmission between ferrets. <i>Journal of General Virology</i> , 2016, 97, 593-601.	1.3	13
124	Machine learning to support visual auditing of home-based lateral flow immunoassay self-test results for SARS-CoV-2 antibodies. <i>Communications Medicine</i> , 2022, 2, .	1.9	13
125	Population implications of the deployment of novel universal vaccines against epidemic and pandemic influenza. <i>Journal of the Royal Society Interface</i> , 2020, 17, 20190879.	1.5	12
126	Acceptability, Usability, and Performance of Lateral Flow Immunoassay Tests for Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: REACT-2 Study of Self-Testing in Nonhealthcare Key Workers. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab496.	0.4	12

#	ARTICLE	IF	CITATIONS
127	Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise. <i>MBio</i> , 2022, 13, .	1.8	12
128	Amino acid substitution D222N from fatal influenza infection affects receptor-binding properties of the influenza A(H1N1)pdm09 virus. <i>Virology</i> , 2015, 484, 15-21.	1.1	10
129	The Emergence of H7N7 Highly Pathogenic Avian Influenza Virus from Low Pathogenicity Avian Influenza Virus Using an in ovo Embryo Culture Model. <i>Viruses</i> , 2020, 12, 920.	1.5	10
130	Quantifying mechanistic traits of influenza viral dynamics using in vitro data. <i>Epidemics</i> , 2020, 33, 100406.	1.5	10
131	Naïve Human Macrophages Are Refractory to SARS-CoV-2 Infection and Exhibit a Modest Inflammatory Response Early in Infection. <i>Viruses</i> , 2022, 14, 441.	1.5	10
132	Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. <i>Vaccine</i> , 2010, 28, 2973-2979.	1.7	9
133	The Functional Study of the N-Terminal Region of Influenza B Virus Nucleoprotein. <i>PLoS ONE</i> , 2015, 10, e0137802.	1.1	9
134	Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. <i>PLoS Pathogens</i> , 2020, 16, e1008716.	2.1	9
135	An engineered avian-origin influenza A virus for pancreatic ductal adenocarcinoma virotherapy. <i>Journal of General Virology</i> , 2016, 97, 2166-2179.	1.3	9
136	Passage of influenza A/H3N2 viruses in human airway cells removes artefactual variants associated with neuraminidase-mediated binding. <i>Journal of General Virology</i> , 2020, 101, 456-466.	1.3	9
137	Potent Virustatic Polymer-Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo. <i>ACS Central Science</i> , 2022, 8, 1238-1257.	5.3	9
138	Pregnancy-related immune suppression leads to altered influenza vaccine recall responses. <i>Clinical Immunology</i> , 2019, 208, 108254.	1.4	8
139	A natural variant in ANP32B impairs influenza virus replication in human cells. <i>Journal of General Virology</i> , 2021, 102, .	1.3	8
140	Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study. <i>EClinicalMedicine</i> , 2022, 48, 101419.	3.2	8
141	Characterising the persistence of RT-PCR positivity and incidence in a community survey of SARS-CoV-2. <i>Wellcome Open Research</i> , 0, 7, 102.	0.9	7
142	A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model. <i>Vaccine</i> , 2022, 40, 2848-2855.	1.7	7
143	Receptor for bat influenza virus uncovers potential risk to humans. <i>Nature</i> , 2019, 567, 35-36.	13.7	6
144	2020 Hindsight: Should evolutionary virologists have expected the unexpected during a pandemic?. Evolution; <i>International Journal of Organic Evolution</i> , 2021, 75, 2311-2316.	1.1	6

#	ARTICLE	IF	CITATIONS
145	Ferret airway epithelial cell cultures support efficient replication of influenza B virus but not mumps virus. <i>Journal of General Virology</i> , 2015, 96, 2092-2098.	1.3	5
146	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. <i>Wellcome Open Research</i> , 0, 6, 358.	0.9	5
147	ACE2: The Only Thing That Matters?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 161-163.	2.5	4
148	Can defective interfering RNAs affect the live attenuated influenza vaccine? â€œ Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1235-1236.	4.6	3
149	The Development of a Reverse Genetics System Enabling the Rescue of Recombinant Avian Influenza Virus, A/turkey/england/50-92/91 (H5N1). <i>Avian Diseases Digest</i> , 2007, 2, e46-e46.	0.0	2
150	A Common <i>TMPRSS2</i> Variant Protects Against Severe COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
151	Amino acid substitutions in the H5N1 avian influenza haemagglutinin alter pH of fusion and receptor binding to promote a highly pathogenic phenotype in chickens. <i>Journal of General Virology</i> , 2021, 102, .	1.3	2
152	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. <i>Wellcome Open Research</i> , 0, 6, 358.	0.9	2
153	Polymer formulated self-amplifying RNA vaccine is partially protective against influenza virus infection in ferrets. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	2
154	Attenuating mutations in the influenza virus genome which may increase the safety of vaccine production. <i>International Congress Series</i> , 2004, 1263, 687-690.	0.2	0
155	Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. <i>Wellcome Open Research</i> , 0, 6, 203.	0.9	0
156	Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. <i>Wellcome Open Research</i> , 0, 6, 203.	0.9	0
157	Title is missing!. , 2020, 16, e1008395.		0
158	Title is missing!. , 2020, 16, e1008395.		0
159	Title is missing!. , 2020, 16, e1008395.		0
160	Title is missing!. , 2020, 16, e1008395.		0
161	Title is missing!. , 2020, 16, e1008716.		0
162	Title is missing!. , 2020, 16, e1008716.		0

#	ARTICLE	IF	CITATIONS
163	Title is missing!. , 2020, 16, e1008716.		0
164	Title is missing!. , 2020, 16, e1008716.		0
165	Title is missing!.. , 2020, 16, e1008716.		0
166	Title is missing!.. , 2020, 16, e1008716.		0